Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer.

Donna E. Reece, Ken A. Foon, Malaya Bhattarcharya-Chatterjee, Doug Adkins, E. Randolph Broun, D. Gerald Connaghan, John F. Dipersio, H. Kent Holland, Dianna A. Howard, Greg A. Hale, Hans G. Klingemann, Rita K. Munn, Anatasios Raptis, Gordon L. Phillips

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

The results of cytotoxic therapy, including dose-intensive therapy requiring autologous stem cell transplantation (ASCT), have been disappointing in patients with metastatic breast cancer, as almost all patients eventually experience disease progression. There has been a renewed interest in immunotherapeutic strategies in this disease, including evaluation of several breast cancer vaccines. In the current study, we describe the results of a program in which the anti-idiotype breast cancer vaccine 11D10 (TriAb) was administered before and after ASCT in patients with metastatic breast cancer chemosensitive to previous conventional therapy. The toxicity of this approach was acceptable, and idiotype-specific humoral and T-cell proliferative responses were observed in the majority of patients within a few weeks post-ASCT. The actuarial 3-year overall survival rate was 48% (95% CI, 32%-64%), while the progression-free survival rate was 32% (95% CI, 19%-45%). Multivariate analysis identified achievement of a strong antibody and cellular immune response to the vaccine as the only significant prognostic factors for outcome. The ability to reliably produce robust immune responses after ASCT is encouraging. Further studies are required to determine if the immune response mediates an antitumor benefit in these patients.

Original languageEnglish
Pages (from-to)S152-157
JournalClinical breast cancer
Volume3 Suppl 4
StatePublished - Feb 2003
Externally publishedYes

Fingerprint Dive into the research topics of 'Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer.'. Together they form a unique fingerprint.

  • Cite this

    Reece, D. E., Foon, K. A., Bhattarcharya-Chatterjee, M., Adkins, D., Broun, E. R., Connaghan, D. G., Dipersio, J. F., Holland, H. K., Howard, D. A., Hale, G. A., Klingemann, H. G., Munn, R. K., Raptis, A., & Phillips, G. L. (2003). Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clinical breast cancer, 3 Suppl 4, S152-157.